Gemini Therapeutics

Gemini is developing first-in-class therapeutics for genetically-defined age-related macular degeneration (AMD) and associated rare genetic diseases. Gemini’s therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and the company’s broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. 

Headquarters Cambridge, MA
Twitter @gemini_thera​
Pipeline Preclinical